Second Sight Medical Products announced that it plans to offer shares of its common stock in a public offering worth $50 million. Los Angeles-based Second Sight priced the underwritten public offering of 10 million shares of common stock at a public offering price of $5 per share to yield gross proceeds of $50 million, according […]
Optical/Ophthalmic
Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant
Glaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant. San Clemente, Calif.–based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levels of the medication for […]
EyeYon Medical corneal endema treatment device wins CE mark
EyeYon Medical announced today that it received CE mark approval for its EndoArt synthetic endothelium replacement implant. Tel Aviv, Israel-based EyeYon designed EndoArt to replace dysfunctional endothelium in patients awaiting human donor tissue as a first-line treatment for patients with chronic corneal edema, as patients with a nonfunctioning endothelium experience excess fluid flowing into the […]
FDA accepts resubmitted NDA for Xipere from Clearside Biomedical, Bausch Health
Bausch Health (NYSE:BHC) and Clearside Biomedical (NSDQ:CLSD) announced today that the FDA accepted their resubmitted new drug application for Xipere. Clearside Biomedical designed the investigational Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for the treatment of macular edema associated with uveitis. Xipere works with Clearside’s proprietary SCS Microinjector to access the back of the […]
Noveome Biotherapeutics inks licensing deal for SipNose drug delivery device
Noveome Biotherapeutics announced that it entered a commercial license agreement to use SipNose’s proprietary drug delivery device. Yokneam, Israel–based SipNose develops its intranasal Cribriform Targeted Device (CT6), which, under the agreement, was licensed to Noveome to deliver the Pittsburgh-based company’s ST266 biologic to the central nervous systems, according to a news release. Get the full story at our […]
CooperVision gains CE mark for kids’ myopia contact lens
CooperVision (NYSE:COO) announced today that its DreamLite night contact lenses received CE mark approval for children with myopia. San Ramon, Calif.–based CooperVision designed its DreamLite night lenses to slow the progression of myopia in children with a refraction of -0.75 D to -5.00 D and a cylindrical refraction with a maximum of -2.50 D, according […]
Alcon inks U.S. selling rights for BlephEx’s eyelid cleaning device
Alcon announced last week that it agreed to a partnership providing it exclusive rights to sell the BlephEx technology and accompanying products. BlephEx’s eyelid cleaning device and the LashCam iR WiFi camera are set to join Alcon’s Systane iLux technology to meet the ocular surface health needs of patients in an office setting, according to […]
FDA approves J&J Vision’s overnight contact lens for myopia management
Johnson & Johnson Vision announced today that it received FDA approval for its Acuvue Abiliti overnight therapeutic lenses. Jacksonville, Fla.-based J&J Vision touts the Acuvue Abiliti as the first and only FDA-approved orthokeratology (ortho-k) contact lens for managing myopia, according to a news release. The company designed the Abiliti overnight ortho-k lenses to be fitted […]
Ocular Therapeutix misses The Street on bottom-line leap
Ocular Therapeutix (NSDQ:OCUL) reported first-quarter results that missed the consensus forecast on Wall Street. The Bedford, Mass.–based eye disease therapeutic developer posted profits of $3.12 million, or $0.04 per share, on sales of $7.34 million for the three months ended March 31, 2021, for a bottom-line leap of 114% on sales growth of 181% compared […]
Glaukos beats The Street in Q1 results
Glaukos (NYSE:GKOS) posted first-quarter results that beat the overall consensus on Wall Street. The San Clemente, Calif.-based ophthalmic medical technology company yesterday reported losses of -$16.469 million, or -36¢ per share, on sales of $67.968 million for the three months ended March 31, for a sales growth of 22.83% compared with Q1 2020. Adjusted to […]
Staar Surgical rises on 44% sales growth in Q1 result
Staar Surgical (NSDQ:STAA) posted first-quarter results that beat the overall consensus on Wall Street. The Lake Forest, Calif.-based implantable eye lenses company yesterday reported profits of $4.99 million, or 10¢ per share, on sales of $50.75 million for the three months ended April 2, for a sales growth of 44.24% compared with Q1 2020. Adjusted to […]
